"We value our continued partnership with the MOH, institutions and the private sector, and look forward to having more opportunities for learning and collaboration, thereby working together for a healthier world," says
Pfizer is very active and has undertaken a number of corporate social responsibility (CSR) initiatives across
Following is the text of the interview:
What initiatives Pfizer has been undertaking in
We have been heavily involved in many high value initiatives aiming at promoting people's health and well-being in
Also, launched 'The hidden faces of diabetes' being a major awareness campaign of serious complications of diabetes in collaboration with Shifaa medical NGO society. The campaign intends to provide blood screening for more than 10,000 people to check their blood sugar and dyslipidemia and provide them with medical counseling. The results will be marked as a surveillance study to help better understand prevalence of diabetes and its complications, including neuropathic pain and heart disease.
As well launched the Saudi National Registry for psoriasis in collaboration with the
What's more, we regularly provide quality summer professional training programs to local pharmaceutical science students to help leverage their professional skills and knowledge of the industry for the benefit of the health care industry in the Kingdom; and provide educational grants to government and institutional health care organizations.
Pfizer has been an active member in the pharmaceutical committee led by the Saudi Chambers of Commerce (CSC) raising recommendations to help leverage professional practices.
Could you give us an idea about your KAEC project?
The new Pfizer manufacturing plant at King Abdullah Economic City (KAEC) will be operational in 2015. It will incorporate medicine manufacturing, especially solid dose, as well as packaging and warehousing facilities. At the total production capacity of 18 million packs per year, the facility -- with a total land area of 32,234 m2 -- will produce a broad range of Pfizer's medicines currently supplied through importation to
What are your plans for facilitating the transfer of technology and creating jobs for Saudis?
The KAEC plant will facilitate the transfer of Pfizer's expertise to the local market in the Kingdom, ensuring that production meets Pfizer's rigorous and globally recognized quality standards. It will also create quality employment opportunities for skilled local manpower and will be instrumental in supplying Pfizer's well established quality pharmaceutical products and making them available for the private, government and health care insurance sectors in the Kingdom and will help accelerate availability of new medications faster than ever.
How do you think your R&D will benefit the local community?
With a growing population and high prevalence of endemic diseases such as diabetes and cardiovascular problems, inflammation and pain, Saudi health care needs are on the rise. Reflecting its commitment to research and development (R&D), Pfizer is working hard to address important unmet needs in the treatment of many prevailing disease areas, including diabetes, cardiovascular disease, pain, oncology, infective disease and rare diseases. Being the head of Pfizer Innovative Pharma (GIP) in AfME, I can certainly elaborate on Pfizer R&D programs in certain therapeutic areas and I will take rheumatoid arthritis (RA) as an example. Pfizer does invest heavily in developing innovative and effective breakthrough medicines that will potentially change the way RA is treated. RA is a serious and disabling disease that affects people in their everyday lives. Unfortunately, many patients worldwide and in our region do not adequately respond or are intolerant to currently available therapies. Again, generally speaking, we are prioritizing our R&D efforts in areas with the greatest scientific and impact promise, including inflammation. Pfizer currently has 20 R&D programs under phase 3 development, and its current pipeline has a total of 84 programs, including new molecular entities (NMEs), additional indications and biosimilars.
What are Pfizer's latest medical solutions?
We have a strong portfolio of new products, market-leading brands and pipeline assets. We are closely working with the MOH, institutions and the private sector, being our strategic partners in
You lead the Global Innovative Pharma across the
Pfizer has evolved itself to ensure it remains the world's premier biopharmaceutical player with an optimal structure. Pfizer's new structure is divided into major business units -- Global Innovative Pharma, Global Established Pharma, Vaccines, Oncology and Consumer. This structure will help unleash growth capabilities of each of these units and will enable us to focus on delivering maximum value to our customers.
What's Pfizer doing to tackle pain as a health issue?
As we all know, pain is among the top health issues in our region today. Pfizer is very concerned with improving the level of care of millions of people with pain in
What's your latest research in providing relief to pain sufferers?
Through major research efforts across multiple modalities, we are developing the medical solutions that will matter most to patients. We are prioritizing R&D efforts in areas with the greatest scientific promise, including neuroscience and pain. Whether through introducing new breakthrough medicines in areas of anti-inflammation and immunotherapy or having new indications approved for our existing market leading pain products, we are working diligently to improve the diagnosis, treatment and management of pain.
Are you collaborating with the MoH and other local agencies in this matter?
Yes, we are partnering with the MOH and other health care partners within
(c)2014 the Arab News (Jeddah, Saudi Arabia)
Visit the Arab News (Jeddah, Saudi Arabia) at www.arabnews.com
Distributed by MCT Information Services